Product Information
STEGLATRO 5 MG TABLET is a brand product labeled by Merck Sharp & Dohme LLC, priced at $11.4362 per EA under NDC 00006536306. Its NADAC has been published 424 times since Aug 22, 2018.
FDA first approved this application on Dec 19, 2017.
Strength
5 mg/1
Manufacturer
Merck Sharp & Dohme LLCNDC
00006536306
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERTUGLIFLOZIN PIDOLATEApproval Type
New Drug (NDA)
FDA Application
NDA209803FDA Approved
12/19/2017
On Market Since
12/19/2017
Price Statistics
The NADAC for STEGLATRO 5 MG TABLET has been published 424 times since Aug 22, 2018, and over the history we have for it it has risen 31.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.4362 per EA |
|---|---|
| All-time high | $11.4535 (May 15, 2024) |
| All-time low | $8.5924 (Oct 17, 2018) |
| 52-week high | $11.4378 |
| 52-week low | $11.4185 |
| Median price | $10.3820 |
| Average price | $10.3752 |
| Largest weekly change | +5.0% (Jan 18, 2023) |
| Weeks tracked | 424 |
| Tracking since | Aug 22, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Merck Sharp & Dohme LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ertugliflozin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of STEGLATRO 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for STEGLATRO 5 MG TABLET, manufactured by Merck Sharp & Dohme LLC, is $11.4362 per EA (NDC 00006536306), effective Sep 30, 2026.
How has the price of STEGLATRO 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for STEGLATRO 5 MG TABLET has risen 31.8%. It has been tracked across 424 weekly CMS publications since Aug 22, 2018.
What are the highest and lowest recorded NADAC prices for STEGLATRO 5 MG TABLET?
Since Aug 22, 2018, the NADAC for STEGLATRO 5 MG TABLET has ranged from a low of $8.5924 (Oct 17, 2018) to a high of $11.4535 (May 15, 2024), with a median of $10.3820 per EA.
Are there cheaper alternatives to STEGLATRO 5 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, STEGLATRO 5 MG TABLET, is $10.9002 per EA — about 5% below STEGLATRO 5 MG TABLET.
Who manufactures STEGLATRO 5 MG TABLET?
STEGLATRO 5 MG TABLET (NDC 00006536306) is labeled by Merck Sharp & Dohme LLC, and CMS classifies it as a brand product.